Ryan Benton is the first patient in the United States to receive human umbilical cord-derived mesenchymal stem cell therapy for Duchenne’s muscular dystrophy. The US FDA granted Ryan this trial under compassionate use. Ryan first began treatments at the Stem Cell Institute in Panama before being able to receive treatments in his hometown of Wichita, Kansas.
Clinical Trials for Multiple Sclerosis and Rheumatoid Arthritis using Umbilical Cord Tissue Mesenchymal Stem Cells
Stem Cell Institute and Medistem Panama founder, Neil Riordan, PhD discusses clinical trials for multiple sclerosis and rheumatoid arthritis using umbilical cord tissue-derived mesenchymal stem cells at our fall stem cell seminar in San Antonio.
For more information about these trials and others, please visit www.translationalbiosciences.com. The multiple sclerosis trial is full but the RA trial is still recruiting as of November 24, 2014.
How do we select umbilical cords for use? Medistem has identified proteins and genes in the cells that allow us to screen hundreds of umbilical cords to select only the ones containing the specific types of cells that have the best anti-inflammatory properties, the best immune modulating capacity and the best ability to stimulate regeneration.
How therapy using umbilical cord tissue-derived mesenchymal stem cells (MSCs) differs from bone marrow transplants used in cancer patients.
Properties of umbilical cord MSCs:
- Modulate the immune system
- Increase the number of T-regulatory cells
- Block clonal expansion of activated T cells
- MSCs in patients with autoimmune diseases don’t work properly
How demyelination occurs in MS patients and how MSCs act on the immune system to slow it down or stop it.
Treated MS patient follow-up survey results at 120 days and 1 year after treatment.
Television news story about Sam Harrell’s return to coaching football after severe MS symptoms forced him into early retirement.
Results from a 172 patient study on treating rheumatoid arthritis with intravenous umbilical cord tissue mesenchymal stem cells in which all patients improved.
These trials may be viewed on the National Institutes of Health web site www.clinicaltrials.gov
Those interested in stem cell therapy for MS may still apply for private treatment on this site.
After FDA Approval, Duchenne’s Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the United States
Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday at Asthma and Allergy Specialists of Wichita, KS following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.
Wichita, KS (PRWEB) September 10, 2014Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.
Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.
This trial, officially entitled “Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD)” marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchenne’s in the United States.
Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.
This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.
The stem cell technology being utilized in this trial was developed by renowned stem cell scientist Neil H. Riordan, PhD. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for their US-based cGMP laboratory partner.
Funding for this trial is being provided by the Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for alternative therapies to people like Ryan.
About Van Strickland, MD
Dr. Strickland came to Wichita in 1979 from his fellowship at the National Jewish Hospital in Denver. Since then he has spent one year in Wyoming, one year in Dallas, Texas and one year in Lee’s Summit Missouri before returning to full-time practice in Wichita, Kansas.
Dr. Strickland has been a clinical faculty member at The University of Kansas School of Medicine in Wichita in the department of Pediatrics and later in the department of internal medicine for most of his years in Wichita.
Dr. Strickland is certified by the American Board of Allergy and Immunology and the American Board of Pediatrics. He graduated from Baylor College of Medicine in Houston, Texas and served a full residency in Pediatrics at Baylor and a fellowship in Allergy and Immunology in Denver at National Jewish. He has trained in allergy and immunology at the University of Texas School of Medicine in Galveston as an elective while at Baylor and was a student on the team with Mary Ann South, MD and John Montgomery, MD who put baby David in the Bubble (Bubble Boy).
Dr. Strickland is a fellow of The American Academy of Allergy, Asthma and Immunology, The American College of Allergy, Asthma and Immunology, The American Association of Certified Allergists, The American Academy of Pediatrics, and The American College of Physicians. Dr Strickland has been recognized in the “Top Doctors in Wichita” listing several times.
Allergy & Asthma Consultants
MHV Strickland M.D.
10021 W. 21st St. Wichita, KS 67205
Phone: +1 (316) 722-4800
Toll-free: +1 (800) 347-4800
Fax: +1 (316) 722-5117
Web Site: http://www.stricklandallergy.com
About Neil Riordan, PhD
Neil Riordan PhD is the co-founder of the Riordan-McKenna Institute, a regenerative orthopedics clinic that will open its doors in Southlake, Texas in late 2014. RMI will offer non-surgical stem cell treatments and stem cell enhanced surgeries for orthopedic conditions. He is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).
Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting seven IRB-approved clinical trials in Panama for autism, multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, and cerebral palsy are scheduled to commence in late 2014 upon IRB approval.
Dr. Riordan’s research team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.
Dr. Riordan has published over 60 scientific articles in international peer-reviewed journals and authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. He is listed on more the 25 patent families, including 11 issued patents including a 2010 patent for a new cellular cancer vaccine.
In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central.
Neil Riordan, PhD
801 E. Southlake Bivd.
Southlake, TX 76092
Phone: +1 (817) 776-8155
Fax: +1 (817) 776-8154
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014
New York, NY (PRWEB) April 09, 2014
The Stem Cell Institute, located in Panama City, Panama, will present an informational umbilical cord stem cell therapy seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.
Neil Riordan PhD – “Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury”
Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.
Jorge Paz-Rodriguez MD – “Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus”
Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.
Light snacks will be served afterwards. Our speakers and stem cell therapy patients will also be on hand to share their personal experiences and answer questions.
Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-tickets-11115112601 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.
About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.
In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.
To-date, SCI has treated over 2000 patients.
For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama
About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.
Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama
Phone: +507 306-2601
Fax: +507 306-2601
About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.
Translational Biosciences webSite: http://www.translationalbiosciences.com
Stem Cell Pioneers featured Dr. Riordan in its February installment of “Ask the Doctor”, a monthly segment that features stem cell scientists and doctors answering questions from readers about stem cell therapy.
Over the next several days, we will share these questions and Dr. Riordan’s answers with our readers.
Question: Are there some conditions such as neurological ones that respond better when the cells are greatly expanded? Is a high quantity essential for success or is that something that may be more of a selling point at some clinics? I have also seen this advertised for COPD and other conditions. It’s almost like the more cells the better, but I would like your opinion.
Dr. Riordan’s Answer: That really depends on the quality of the cells after expansion. If they are still robust, not senescent, and still have a good secretion profile, then the more the better may be useful up to a point. If you take a small pool of starter cells and expand them to exhaustion, then I don’t think you are going to have a very good product. The MSCs used in Panama are not expanded beyond passage 5—a point at which there is no senescence in the population and they have a robust cytokine secretion profile. In order to use only cells that meet our release criteria, cells from approximately one (1.2 to be exact) out of 10 donated umbilical cords are used.
Contrast that to cells from a patient’s own fat tissue that are expanded. Firstly, the starting cells may, and many times are not very robust—they secrete little or no beneficial cytokines or chemokines, and must be expanded to hilt in order to hit the cell number. Please see my answer to number 7 for more on this subject.
This brings up a slightly different, yet related topic. There has been a lot of talk at recent meetings about more defined endpoints for the cells being used, and I couldn’t agree more. There are MSCs from bone marrow, menstrual blood, fat tissue, umbilical cord (even different parts of the umbilical cord—around the blood vessels, from the Wharton’s jelly, from the subepithelium, from the cord blood itself—which are most likely contaminants from a bruised placenta rather than the blood), teeth, amniotic membrane, amniotic fluid just to name sources in the “we didn’t mess with mother nature” adult stem cell world. Add to that the infinite variables when you consider the age and physical condition of the donor, particularly when using adipose or bone marrow as a source material and we, as a field, could be saying almost anything by using the term, “mesenchymal stem cell.” I think it is time that there is standardization in the field beyond the current definition of expressing/not expressing certain surface markers and the ability to differentiate into fat, bone, and cartilage. That standardization could come from using endpoints such as “remaining proliferative capacity (the number of doublings achievable in culture from the treatment cell bank), the secretome, even if there is standardization of one or two molecules, such as HGF, or one of the prostaglandins.
In the future I believe the field will take it a step further by measuring, even by a surrogate marker, the potential effects of the cells on the target condition. In the case of autoimmunity the cells and their secretions could be tested for their capacity to modulate the immune system. In the case of inflammatory conditions, the cells and their secretions could be tested for the ability to control or block inflammation.
Umbilical Cord Stem Cells: Regeneration, Repair, Inflammation and Autoimmunity – Neil Riordan PhD (Part 2 of 2)
In part 2, Dr. Riordan discusses how mesenchymal stem cells can affect tissue repair in spinal cord injury and in heart failure; benefit to heart is not the actual MSCs modeling new tissue. It is due to the trophic effects of MSC secretions; In rats, severed spinal cords re-grew after MSCs were implanted but the human MSCs did not form new cord tissue. The trophic factors secreted by the MSCs enable the spinal cord to repair itself.; Trophic factors from MSCs modulate the immune system by blocking clonal expansion of cytotoxic T-cells; There are 35 ongoing clinical trials using mesenchymal stem cells for autoimmune diseases; Safety of donor MSCs; Every mother has MSCs from each baby she has carried; Mothers have a lower incidence of autoimmune disease; Lifespan of mothers increased linearly with each child up to 14; There are 85 ongoing clinical trials using donor MSCs. Allogeneic MSCs from bone marrow have been approved in Canada and New Zealand to treat graft vs. host disease; limbal cells used in corneal transplants are MSCs; MSCs are useful in preventing donated organ rejection; glioma growth was found to be inhibited by MSCs; MSCs eliminated breast cancer in rats.
After stem cell therapy at the Stem Cell Institute in Panama, C-6 incomplete spinal cord injury patient, Daniel Campbell describes how his condition has improved since his first treatment. Daniel is in Panama for his second treatment during this recording
“…The trajectory of my recovery drastically took an upward turn. I got grip back, got a lot stronger and my blood pressure issue sort of went out the window. My lower back started firing so when I lean back in my chair, I don’t just fall.
Most recently my hip flexors started firing in certain positions so I can assist the therapist while crawling. Bowel and bladder sensation has gotten better. I have hot and cold sensation in my hands now. Incontinence is a thing of the past.
Multiple Sclerosis Radio – “Stem cells are your body’s natural healing mechanism” – Neil Riordan PhD
For anyone who missed Dr. Riordan’s talk on MS Radio yesterday, below is a link to the replay. Did you know that by age 30, 96% of the mesenchymal stem cells are gone from a person’s bone marrow? Why is MS a disease of the immune system? How can an automated machine analyze a sample of lecithin and buffer that contains no cells and show that it contains 10 million cells per ml? Tune in for these and more.
TODAY ON MULTIPLE SCLEROSIS RADIO!
Dr. Neil Riordan, Founder of Stem Cell Institute
Tuesday Feb 5, 2013 at 2 pm EST.
LISTEN ONLINE: Multiple Sclerosis Radio
or call in Join Us LIVE On Air
A Different Approach
Sergeant Preston Walker
Courtesy Sergeant Preston Walker
After undergoing conventional therapy for MS for several years, Fort Worth police sergeant Preston Walker learned about a new therapy for autoimmune disorders. Researchers were utilizing adult stem cells derived from cord blood at The Institute of Cellular Medicine in Costa Rica. Walker inquired about the potential of using stem cells for multiple sclerosis.
“We knew that if the treatment worked, the potential benefits for multiple sclerosis patients could be limitless,” says Walker.
Dr. Neil Riordan, CEO of the Institute, suggested a therapy under consideration – using stem cells derived from a patient’s fat tissue. In May 2008, Walker flew to the clinic where doctors removed samples of his abdominal fat through a mini-liposuction, drawing out stem cells, which were later re-injected. According to Dr. Riordan, Walker and a colleague were the first to undergo this treatment protocol. “My quality of life has improved significantly,” Walker told the Post. “The problems with depression, fatigue, and balance have been corrected. I feel really good.”
In June 2009, Walker, who continues to take Avonex as a maintenance drug, plans a return trip to Costa Rica for a “tune-up,” as he puts it. “I’m curious to see if they can further improve my cognitive abilities.”
Fox 4 News: A Fort Worth police officer has returned from Central America after having a cutting edge medical procedure to help cure his multiple sclerosis. Last year we told you about Sergeant Preston Walker tonight Larry Barriger updates us on how he is feeling following his stem cell transplant.
Sergeant Preston Walker has always been active. With a demanding job at the Fort Worth Police Department, a wife, and young children, he doesn’t have time to slow down. But about 8 years ago he didn’t have a choice. MS started taking a toll making him limp when he walked, fatigue easily, even everyday conversation was a chore.
“I can sit here and talk but trying to come up with actual words to say and really construct a sentence that people would understand was sometimes very difficult.”
Medicine helped keep the disease in remission but Preston wanted more. A chance for a cure.
“I wasn’t prepared to just let it stay in remission without me trying to do something, especially if there is an option out there to address it.”
Sergeant Walker was initially planning to have his treatment done in China but he says the political situation seemed unstable, so he started looking online. He found another center that was doing adult stem cell treatment in Central America.
The procedure, a stem cell transplant was expensive but last October police officers from Fort Worth and Dallas teamed up to help raise money for the trip and the treatment. Last March Preston and fellow MS patient Richard Humphries flew to the Institute for Cellular Medicine, both underwent a stem cell transplant, a cutting edge medical procedure not approved in the US. Both took a risk on such a new treatment, both said they have seen marked improvement.
“I haven’t felt this good in 10 years. I don’t have any of the fatigue issues, all of the cognitive lack of clarity, that cloud has been lifted.”
Walker says doctors at the Institute will be keeping up with him and Richard over the coming months and years to determine how successful the treatment was. He is hoping his improvements last and that the research leads to a cure for his and other’s multiple sclerosis.
It seems like a pretty simple task for a police officer just sitting and working on a computer. Just a couple of years ago, multiple sclerosis made that almost impossible for Fortworth Police Officer Preston Walker. New at 6 CBS 11’s Joe Thomas says Walker credits friends for recovery some feel is a miracle.
A year ago Preston Walker did not think he’d still be in uniform. Walker found out he has multiple sclerosis. He suffered chronic fatigue and began losing use of his legs.
I felt like my cognition was really declining at a rapid pace. I really felt if I made it through the end of the year, last year, I probably wouldn’t be employed any longer because the cognition just wasn’t there.
His fellow police officers held a hockey-game fundraiser to help him afford a revolutionary treatment. Walker and another MS patient, Richard Humphreys, went to Costa Rica. For the first time ever, doctors took samples of their fat, drew stem cells from it, and reinjected it. Their symptoms nearly vanished.
I’ll suffer from any of those symptoms that we talked about, the depression, the fatigue, the little cognitive cloud. I mean it’ll still hit occasionally, but its no where near every day or every moment of every day like it was.
If we or somebody doesn’t become a guinea pig, then how can that benefit others?
They led the way to a treatment that is now helped ease the suffering of dozens of others. Joel Thomas, CBS 11 News.
Dr. Riordan discusses current US FDA oversight of adult stem cell treatments, “practice of medicine” treatments that are neither regulated nor approved by the FDA, historical examples of successful medical procedures such as bariatric surgery, liposuction and ulcer treatments which were violently opposed by researchers, physicians and companies with competing financial interests.